BioMachines Announces Acquisition and new Management
News Feb 06, 2006
Clearview Limited has announced that it has purchased BioMachines on Dec. 29, 2005. Sam Tetlow, founding partner of Clearview and a principal with Research Triangle Ventures, is now chairman of BioMachines.
He has named Tom Larrichio, formerly vice president of business development at TriVirix International, Inc., as BioMachines' chief executive officer.
"After a comprehensive review of the genomic and proteomics industry, we believe BioMachines is uniquely positioned to achieve excellent commercial results from its market-proven, proprietary products," said Tetlow.
"The company has deep scientific expertise and a pipeline of novel diagnostic tools that will have a meaningful impact to the work of leading drug discovery researchers, especially those working in the growing field of proteomics."
Tetlow said he selected Larrichio as BioMachines' new CEO because of his sales acumen, extensive management experience and life science knowledge.
He adds, "Tom has the requisite commercial expertise to take the company to the next level."
Analytical Tool Predicts Disease-Causing GenesNews
Predicting genes that can cause disease due to the production of truncated or altered proteins that take on a new or different function, rather than those that lose their function, is now possible thanks to an international team of researchers that has developed a new analytical tool to effectively and efficiently predict such candidate genes.
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE